Comparative Evaluation of Three Pulpotomy Agents for Permanent Mature Molars With Irreversible Pulpitis
Launched by AIN SHAMS UNIVERSITY · Jan 22, 2024
Trial Information
Current as of August 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the effectiveness of three different materials used in a dental procedure called pulpotomy, which is a treatment for permanent molars with irreversible pulpitis (a painful condition where the pulp inside the tooth is inflamed and cannot heal). The study will compare two new types of calcium silicate materials to a commonly used material called MTA. Researchers will look at how well these materials help reduce inflammation and improve clinical and X-ray outcomes for the patients involved.
To participate in this trial, individuals must have healthy permanent molars showing clear signs of irreversible pulpitis, such as sharp or prolonged pain and sensitivity to temperature changes. Eligible participants should not have any other dental issues or health conditions that could complicate the treatment, like diabetes or immune system problems. During the trial, participants will undergo a standard dental procedure, and their progress will be monitored through check-ups and X-rays. This study aims to find better treatment options for patients suffering from this dental condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Participants with permanent molars considered as having clinical signs and symptoms consistent with a diagnosis of irreversible pulpitis if they presented with the following chief complaint:
- • Intermittent or spontaneous, sharp or dull, localized, diffuse, or referred pain.
- • Rapid exposure to dramatic temperature changes elicited heightened and --prolonged episodes of pain even after the thermal stimulus has been removed.
- • Participants without signs and symptoms of apical periodontitis
- • Periodontally healthy permanent molars
- • Systemically healthy patients without any history of long-acting NSAIDs intake in the past one week will be included to eliminate any confounding factors.
- Exclusion Criteria:
- • Non-restorable teeth with cracks or subgingival caries, associated sinus or swelling, immature roots, periapical rarefaction (PAI score ≥ 3).
- • Poor periodontal support.
- • Negative response to pulp sensibility tests.
- • Diabetic, immune-compromised, pregnant patients
- • Patient had a positive history of antibiotic use in the past 1 month or required antibiotic prophylaxis
- • The tooth was previously accessed
- • The tooth had an inflamed pulp in which bleeding could not be controlled within 10 minutes.
About Ain Shams University
Ain Shams University, established in Cairo, Egypt, is a prestigious higher education institution renowned for its commitment to academic excellence and research innovation. As a clinical trial sponsor, the university leverages its extensive resources and expertise in various medical and scientific disciplines to advance healthcare through rigorous research initiatives. With a focus on ethical practices and adherence to regulatory standards, Ain Shams University aims to contribute to the development of new therapies and improve patient outcomes, fostering collaboration among researchers, healthcare professionals, and industry partners in the pursuit of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported